{"title":"癌症治疗的长期后果：CAR - T细胞治疗后的认知障碍","authors":"Kathrin Gabriel, Sebastian Kobold","doi":"10.1038/s41392-025-02324-6","DOIUrl":null,"url":null,"abstract":"<p>A recent publication by Geraghty et al. in <i>Cell</i> investigates how chimeric antigen receptor (CAR) T cell therapy can induce cognitive impairment in murine models of both central nervous system (CNS)- and non-CNS-based tumors.<sup>1</sup> The authors identified persistent neuroinflammation as a key mechanism underlying these cognitive deficits and successfully explored novel therapeutic strategies, including microglial depletion and CCR3 blockade (Fig. 1).<sup>1</sup></p><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 1</b></figcaption><picture><source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02324-6/MediaObjects/41392_2025_2324_Fig1_HTML.png?as=webp\" type=\"image/webp\"/><img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"324\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02324-6/MediaObjects/41392_2025_2324_Fig1_HTML.png\" width=\"685\"/></picture><p>Temporal overview of onset and duration of side effects following administration of CAR T cell therapy. Compared to more acute toxicities such as CRS and ICANS, cognitive impairment can also be seen after months and years following CAR T cell administration. Underlying mechanisms are characterized by distinct neurobiological alterations such as elevated cerebrospinal fluid (CSF) cytokine and chemokine levels, reduced subcortical oligodendrocyte numbers, and microglial activation. Figure created in BioRender. G., K. (2025)</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"192 1","pages":""},"PeriodicalIF":40.8000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy\",\"authors\":\"Kathrin Gabriel, Sebastian Kobold\",\"doi\":\"10.1038/s41392-025-02324-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A recent publication by Geraghty et al. in <i>Cell</i> investigates how chimeric antigen receptor (CAR) T cell therapy can induce cognitive impairment in murine models of both central nervous system (CNS)- and non-CNS-based tumors.<sup>1</sup> The authors identified persistent neuroinflammation as a key mechanism underlying these cognitive deficits and successfully explored novel therapeutic strategies, including microglial depletion and CCR3 blockade (Fig. 1).<sup>1</sup></p><figure><figcaption><b data-test=\\\"figure-caption-text\\\">Fig. 1</b></figcaption><picture><source srcset=\\\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02324-6/MediaObjects/41392_2025_2324_Fig1_HTML.png?as=webp\\\" type=\\\"image/webp\\\"/><img alt=\\\"figure 1\\\" aria-describedby=\\\"Fig1\\\" height=\\\"324\\\" loading=\\\"lazy\\\" src=\\\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02324-6/MediaObjects/41392_2025_2324_Fig1_HTML.png\\\" width=\\\"685\\\"/></picture><p>Temporal overview of onset and duration of side effects following administration of CAR T cell therapy. Compared to more acute toxicities such as CRS and ICANS, cognitive impairment can also be seen after months and years following CAR T cell administration. Underlying mechanisms are characterized by distinct neurobiological alterations such as elevated cerebrospinal fluid (CSF) cytokine and chemokine levels, reduced subcortical oligodendrocyte numbers, and microglial activation. Figure created in BioRender. G., K. (2025)</p><span>Full size image</span><svg aria-hidden=\\\"true\\\" focusable=\\\"false\\\" height=\\\"16\\\" role=\\\"img\\\" width=\\\"16\\\"><use xlink:href=\\\"#icon-eds-i-chevron-right-small\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"></use></svg></figure>\",\"PeriodicalId\":21766,\"journal\":{\"name\":\"Signal Transduction and Targeted Therapy\",\"volume\":\"192 1\",\"pages\":\"\"},\"PeriodicalIF\":40.8000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Signal Transduction and Targeted Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41392-025-02324-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signal Transduction and Targeted Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41392-025-02324-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy
A recent publication by Geraghty et al. in Cell investigates how chimeric antigen receptor (CAR) T cell therapy can induce cognitive impairment in murine models of both central nervous system (CNS)- and non-CNS-based tumors.1 The authors identified persistent neuroinflammation as a key mechanism underlying these cognitive deficits and successfully explored novel therapeutic strategies, including microglial depletion and CCR3 blockade (Fig. 1).1
Fig. 1
Temporal overview of onset and duration of side effects following administration of CAR T cell therapy. Compared to more acute toxicities such as CRS and ICANS, cognitive impairment can also be seen after months and years following CAR T cell administration. Underlying mechanisms are characterized by distinct neurobiological alterations such as elevated cerebrospinal fluid (CSF) cytokine and chemokine levels, reduced subcortical oligodendrocyte numbers, and microglial activation. Figure created in BioRender. G., K. (2025)
期刊介绍：
Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy.
Scope: The journal covers research on major human diseases, including, but not limited to:
Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
